Convergent Therapeutics, Inc.

We are excited to share our new company brand, reflecting our mission to unlock the full potential of alpha radioantibodies to benefit the lives of patients who are battling cancer. Learn more about Convergent, CONV01-α and our science: https://convergentrx.com/

Yesterday, we announced the appointment of Barbara Duncan to our Board of Directors. "Barbara is a welcome addition to our Board of Directors, bringing deep experience in biopharmaceutical leadership," said Convergent's Co-founder and CEO, Philip Kantoff, MD. "We are confident that she will be an important asset to the Board as we continue to drive our pipeline through clinical development." To read the full announcement, visit: https://lnkd.in/eWDNEkiy

This morning, we announced the receipt of the first shipments of non-carrier added (n.c.a.) Actinium 225 (Ac-225) from Cardinal Health to support the CONVERGE-01 Phase 2 clinical trial. Ac-225 is a high-energy, alpha-emitting radioisotope of great interest for the treatment of cancer, as it is thought to carry sufficient radiation to cause cancer cell death when bound to a targeting antibody. "This shipment will support Convergent's lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225. CONV01-α is currently being investigated as a potentially groundbreaking treatment for prostate cancer,” said Convergent's Co-founder and CEO, Philip Kantoff, MD. To read the full announcement, visit: https://lnkd.in/egdtqTcY

This morning, we announced the first patient has been dosed with CONV01-α in the Phase II CONVERGE-01 trial evaluating CONV01-α, Ac-225 rosopatamab tetraxetan, for the treatment of patients with prostate-specific membrane antigen (PSMA) PET-positive metastatic castration resistant prostate cancer. We are also excited to welcome Richard Messmann, M.D., M.H.S., M.Sc., as Chief Medical Officer to lead development of CONV01-α. In addition, Novo Holdings invests $40 million in Series A Extension to advance clinical development of radiopharmaceuticals, increasing the total Series A raise to $130 million. To learn more about our pipeline and corporate updates, and read the full announcement, visit: https://lnkd.in/eXZ9xcGk

NorthStar Medical Radioisotopes and Convergent Therapeutics, Inc. Expand Strategic Collaboration Around CONV01-α https://lnkd.in/eYuV4SPM

Join us in San Diego for the 2024 US Targeted Radiopharmaceuticals Summit. Dr. Jones Nauseef, MD PhD, Senior Medical Director at Convergent Therapeutics will be presenting an update on our Actinium-225 PSMA targeted radioantibody, CONV01-α. “Targeted radiotherapies are an emerging and exciting class of anti-cancer therapeutics. Our lead asset, CONV01-alpha, is an actinium-conjugated monoclonal antibody against PSMA. I’m excited to join colleagues at Hanson Wade’s 3rd Annual Targeted Radiopharmaceuticals Summit and present on past successes and the future promise of CONV01-alpha in castration resistant prostate cancer.” For more information, visit: https://lnkd.in/e5YB65Er #ProstateCancer #Oncology #PSMA

Today, we announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, our lead candidate for the treatment of patients with advanced prostate cancer.   “While we have already treated well over 100 advanced prostate cancer patients in the context of investigator INDs, this new IND will allow us to rapidly advance CONV01-α into Phase 3 studies and expand the scope of clinical development of CONV01-α as a monotherapy and in combination with other cancer therapies,” said Convergent’s Co-founder and CEO, Philip Kantoff, MD.   We are on track to conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025.   To learn more about CONV01-α and read the full announcement, visit: https://lnkd.in/esyxbsfb   #ProstateCancer #Oncology

Today, the American Society of Clinical Oncology (ASCO) announced that Convergent Co-Founder and CEO Dr. Philip Kantoff has been awarded the Excellence in Teaching Award. This award recognizes teaching as a vital part of #cancer care for the population and underscores ASCO’s belief that teaching is as important to the future of cancer medicine as are research, care delivery and clinical work.   We are proud of the work Dr. Kantoff has done throughout his career to advance cancer treatment, including his dedication to mentorship of residents, clinical and post-doctoral fellows, and trainees.   Dr. Kantoff will be honored at the upcoming ASCO Annual Meeting in Chicago. For more on the award, visit https://lnkd.in/eG7KK3SE #ASCO2024 #ProstateCancer #Oncology

This morning, Convergent announced the appointment of Scott Myers as Chairman of our Board of Directors. "Scott brings an enormous amount of experience and expertise as both a Chief Executive Officer as well as a board member and chair in numerous life science companies," says Dr. Philip Kantoff, Co-Founder and CEO of Convergent.  Read more here: https://lnkd.in/eYH-cvTQ

Our team is heading to San Francisco for the 42nd Annual J.P. Morgan Healthcare Conference and will be sharing more about our exciting targeted radiotherapy. We look forward to hearing expert insights on trends shaping the industry now, and in the year ahead. We can’t wait to see everyone there! #JPM24 #radiopharmaceuticals #prostatecancer